Wang J, Zhao D, Ding CZ, Guo F, Wu LN, Huang FJ, et al
These statements have not been evaluated by the FDA
Gaucher, a rare disease affecting about one in every 50,000 people in the world population and up to one in 500 people in people of Ashkenazi (eastern and central European) Jewish heritage
They reduce Melanin production, dullness, and improve texture remarkably well
For nauseathe most common GLP-1 side effectnote whether it occurs primarily after injections, with meals, or throughout the day
Future studies are needed to determine if there is a benefit in NASH reduction or fibrosis regression